In March 2025, French pharmaceutical and consumer healthcare company Mayoly officially launched a representative office in Ho Chi Minh City, marking its formal entry into the Vietnamese market.
Although the group has been active in Vietnam through its Ipsen consumer healthcare brand, the new office will now serve as a vital strategic base, supporting in-depth market analysis and facilitating the development of key partnerships within the country.
Vietnam’s healthcare sector is witnessing rapid growth, and Mayoly intends to deepen its engagement by leveraging its extensive portfolio of well-known digestive health products. These include flagship brands such as Smecta, Forlax, Fortrans, MeteoSpasmyl, and Chophytol, alongside Tanakan, a product aimed at enhancing mental performance.
In conjunction with the office launch, Mayoly also announced a strategic collaboration with local distributor Hoang Duc. This partnership is expected to help Mayoly bring more innovative and high-quality healthcare solutions to Vietnamese patients and consumers.
Emmanuel Paint, Executive Vice President of Global Sales at Mayoly, highlighted the importance of the company’s strong commercial network across Southeast Asia. He emphasized that the new office in Vietnam, along with a regional hub in Singapore, underpins the company’s long-term growth strategy and its commitment to public health.
Mayoly, which reported EUR 560 million in revenue and 5% growth in 2024, currently operates in 21 countries and distributes its products in over 100 nations globally.
(Source: Vietnam Investment Review)
